Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m.
ET NEW HAVEN, Conn. , Nov. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.
(Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced financial results for the quarter ended September 30, 2024, as well as provided business updates. "Our team has made excellent progress advancing our clinical programs this year, and we are eagerly anticipating the upcoming clinical results starting in December," said Jennifer Good , President and CEO of Trevi Therapeutics. "Positive results over the upcoming months would bring us closer to potentially addressing the significant unmet need and market opportunity in both chronic cough in IPF and RCC through Haduvio's unique mechanism.
" Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agon.
